Brachytherapy for the urologist: A multidisciplinary team update for 2019

Abstract

Brachytherapy is a well-established treatment for localised prostate cancer. Urologists are often tasked with discussing all available treatment options with the newly diagnosed patient. Unlike radical prostatectomy and external beam radiotherapy, knowledge of brachytherapy may be limited. The aim of this article is to provide an up-to-date guide on patient selection, modern brachytherapy techniques and the management of side effects, such that the core urologist can be more confident in both discussing initial treatment options and the long-term management of brachytherapy patients.

Level of Evidence: Level 5 - review article

Keywords

Oncology oncology (prostate)prostate cancer radiology brachytherapy

Get full access to this article

View all access options for this article.

References

Office for National Statistics. Cancer registration statistics England, https://www.ons.gov.uk/peoplepopulationandcommunity/healthandsocialcare/conditionsanddiseases/datasets/cancerregistrationstatisticscancerregistrationstatisticsengland (2018, accessed February 2019).

Sommers

Beard

D’Amico

et al. Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 2008; 113: 2058–2067.

Hall

Boyd

Lippert

et al. Why patients choose prostatectomy or brachytherapy for localized prostate cancer: Results of a descriptive survey. Urology 2003; 61: 402–407.

Porter

Blasko

Grimm

et al. Brachytherapy for prostate cancer. CA Cancer J Clin 1995; 45:165–178.

Salembier

Lavagnini

Nickers

et al. Tumour and target volumes in permanent prostate brachytherapy: A supplement to the ESTRO/EAU/EORTC recommendations on prostate brachytherapy. Radiother Oncol 2007; 83: 3–10

Health Research Authority. PIVOTALBoost Trial, https://www.hra.nhs.uk/planning-and-improving-research/application-summaries/research-summaries/pivotalboost/ (2017, accessed February 2019).

D’Amico

Whittington

Malkowicz

et al. A biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.

European Association of Urology. EAU-ESTRO-ESUR-SIOG guidelines on prostate cancer, https://uroweb.org/wp-content/uploads/09-Prostate-Cancer_2017_web.pdf (2017, accessed June 2018).

Langley

SEM

Soares

Uribe

et al. Long-term oncological outcomes and toxicity in 597 men aged ⩽60 years at time of low-dose-rate brachytherapy for localised prostate cancer. BJU Int 2018; 121: 38–45.

10.

Morris

Tyldesley

Pai

et al. ASCENDE-RT*: A multicenter, randomized trial of dose-escalated external beam radiation therapy (EBRT-B) versus low-dose-rate brachytherapy (LDR-B) for men with unfavorable-risk localized prostate cancer. J Clin Oncol 2015; 33: 3-3.

11.

Breyer

Davis

Cowan

et al. Incidence of bladder neck contracture after robot-assisted laparoscopic and open radical prostatectomy. BJU Int 2010; 106: 1734–1738.

12.

Parihar

Kim

IY.

Bladder neck contracture-incidence and management following contemporary robot assisted radical prostatectomy technique. Prostate Int 2014; 2: 12–18.

13.

Moran

Stutz

Gurel

MH.

Prostate brachytherapy can be performed in selected patients after transurethral resection of the prostate. Int J Radiat Oncol Biol Phys 2004; 59: 392–396.

14.

Henderson

Langley

Laing

RW.

Is bicalutamide equivalent to goserelin for prostate volume reduction before radiation therapy? A prospective, observational study. Clin Oncol (R Coll Radiol) 2003; 15: 318–321.

15.

Stone

Stock

RG.

Prostate brachytherapy in patients with prostate volumes >/= 50 cm(3): dosimetic analysis of implant quality. Int J Radiat Oncol Biol Phys 2000; 46: 1199–1204.

16.

Brousil

Hussain

Lynch

et al. Modified transurethral resection of the prostate (TURP) for men with moderate lower urinary tract symptoms (LUTS) before brachytherapy is safe and feasible. BJU Int 2015; 115: 4580–4586.

17.

Ash

Flynn

Battermann

et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000; 57: 315–321.

18.

Kovács

Pötter

Loch

et al. GEC/ESTRO-EAU recommendations on temporary brachytherapy using stepping sources for localised prostate cancer. Oncol 2005; 74: 137–148.

19.

Hoskin

Colombo

Henry

et al. ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update. Radiother Oncol 2013;107: 325–332.

20.

Roach

III Hanks

Thames

et al. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006; 65: 965–974.

21.

Makarewicz

Lebioda

Terlikiewicz

et al. PSA bouncing after brachytherapy HDR and external beam radiation therapy: A study of 121 patients with minimum 5-years follow-up. J Contemp Brachytherapy 2009; 1: 92–96.

22.

Merrick

Butler

Wallner

et al. Prostate-specific antigen spikes after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2002; 54: 450–456.

23.

Cavanagh

Blasko

Grimm

et al. Transient elevation of serum prostate-specific antigen following (125)I/(103)Pd brachytherapy for localized prostate cancer. Semin Urol Oncol 2000; 18: 160–165.

24.

Stone

Stock

White

et al. Patterns of local failure following prostate brachytherapy. J Urol 2007; 177: 1759–1763; discussion 1763–1764.

25.

Oppenheimer

Weinberg

Hollenberg

et al. Magnetic resonance imaging of recurrent prostate cancer. J Clin Imaging Sci 2016; 6: 18.

26.

Quero

Vercellino

de Kerviler

et al. 18F-choline PET/CT and prostate MRI for staging patients with biochemical relapse after irradiation for prostate cancer. Clin Nucl Med 2015; 40: e492–e495.

27.

Einspieler

Rauscher

Düwel

et al. Detection efficacy of hybrid ⁶⁸Ga-PSMA ligand PET/CT in prostate cancer patients with biochemical recurrence after primary radiation therapy defined by Phoenix criteria. J Nucl Med 2017; 58: 1081–1087.

28.

Schlussel Markovic

Buckstein

Stone

et al. Outcomes and toxicities in patients with intermediate-risk prostate cancer treated with brachytherapy alone or brachytherapy and supplemental external beam radiation therapy. BJU Int 2018; 121: 774–780.

29.

Crook

McLean

Catton

et al. Factors influencing risk of acute urinary retention after TRUS-guided permanent prostate seed implantation. Int J Radiat Oncol Biol Phys 2002; 52: 453–460

30.

Locke

Ellis

Wallner

et al. Risk factors for acute urinary retention requiring temporary intermittent catheterization after prostate brachytherapy: A prospective study. Int J Radiat Oncol Biol Phys 2002; 52: 712–719.

31.

Elliott

Meng

Elkin

et al. Incidence of urethral stricture after primary treatment for prostate cancer: Data from CaPSURE. J Urol 2007; 178: 529–534

32.

Earley

Abdelbaky

Cunningham

et al. Correlation between prostate brachytherapy-related urethral stricture and peri-apical urethral dosimetry: A matched case-control study. Radiother Oncol 2012; 104: 187–191.

33.

Zelefsky

Hollister

Raben

et al. Five-year biochemical outcome and toxicity with transperineal CT-planned permanent I-125 prostate implantation for patients with localized prostate cancer. Int J Radiat Oncol Biol Phys 2000; 47: 1261–1266.

34.

Hofer

Gonzalez

CM.

Management of radiation-induced urethral strictures. Transl Androl Urol 2015; 4: 66–71

35.

Stock

Stone

Iannuzzi

Sexual potency following interactive ultrasound-guided brachytherapy for prostate cancer. Int J Radiat Oncol Biol Phys 1996; 35: 267–272.

36.

Fulmer

Bissonette

Petroni

et al. Prospective assessment of voiding and sexual function after treatment for localized prostate carcinoma: Comparison of radical prostatectomy to hormonobrachytherapy with and without external beam radiotherapy. Cancer 2001; 91: 2046–2055.

37.

Zhang

et al. Early channel transurethral resection of the prostate for patients with urinary retention after brachytherapy. J Zhejiang Univ Sci B 2014; 15: 756–760.

38.

Merrick

Butler

Wallner

et al. Effect of transurethral resection on urinary quality of life after permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2004; 58: 81–88.

39.

Flam

Peyromaure

Chauveinc

et al. Post-brachytherapy transurethral resection of the prostate in patients with localized prostate cancer. J Urol 2004;172: 108–111.

40.

Paparel

Cronin

Savage

et al. Oncologic outcome and patterns of recurrence after salvage radical prostatectomy. Eur Urol 2009; 55: 404–410.

41.

Dason

Wong

Allard

et al. A High-intensity focused ultrasound (HIFU) as salvage therapy for radio-recurrent prostate cancer: Predictors of disease response. Int Braz J Urol 2018; 44: 248–257.

42.

Henríquez

Sancho

Hervás

et al. Salvage brachytherapy in prostate local recurrence after radiation therapy: Predicting factors for control and toxicity. Radiat Oncol 2014; 9: 102.

43.

Kunogi

Wakumoto

Yamaguchi

et al. Focal partial salvage low-dose-rate brachytherapy for local recurrent prostate cancer aft permanent prostate brachytherapy with a review of the literature. J Contemp Brachytherapy 2016; 8: 165–172.

44.

Peters

Maenhout

van der Voort van Zyp

et al. Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary raid therapy: A retrospective study regarding toxicity, biochemical outcome and quality of life. Radiother Oncol 2014; 112: 77–82.